Endothelial-mesenchymal transition is an important contributor to pathophysiological vascular remodeling in pulmonary hypertension, and its potential reversibility offers insights for new therapies.
All forms of pulmonary hypertension are characterized by structural changes in pulmonary arteries. Increased numbers of cells expressing alpha-smooth muscle (alpha-SM) actin is a nearly universal finding in the remodeled artery. Traditionally, it was assumed that resident smooth muscle cells were the exclusive source of these newly appearing alpha-SM actin-expressing cells. However, rapidly emerging experimental evidence suggests other, alternative cellular sources of these cells. One possibility is that endothelial cells can transition into mesenchymal cells expressing alpha-SM actin and that this process contributes to the accumulation of SM-like cells in vascular pathologies. We review the evidence that endothelial-mesenchymal transition is an important contributor to cardiac and vascular development as well as to pathophysiological vascular remodeling. Recent work has provided evidence for the role of transforming growth factor-beta, Wnt, and Notch signaling in this process. The potential roles of matrix metalloproteinases and serine proteases are also discussed. Importantly, endothelial-mesenchymal transition may be reversible. Thus insights into the mechanisms controlling endothelial-mesenchymal transition are relevant to vascular remodeling and are important as we consider new therapies aimed at reversing pulmonary vascular remodeling.
Arciniegas et al. (Sat,) conducted a review in Chronic pulmonary hypertension. Endothelial-to-mesenchymal transition (topic of review) was evaluated. Endothelial-mesenchymal transition is an important contributor to pathophysiological vascular remodeling in pulmonary hypertension, and its potential reversibility offers insights for new therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: